The strength of our study lies in addressing this gap by combining bioinformatics analyses with multi-layered verification using clinical samples, systematically confirming the expression patterns and regulatory interactions of DACH1 and DNMT1 at critical stages of CRC progression. This evidence concerns the gene DNMT1 and colorectal carcinoma.